Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

PharmaCyte Biotech, Inc. (PMCB)

2.91   0.06 (2.11%) 03-31 16:00
Open: 2.86 Pre. Close: 2.85
High: 2.94 Low: 2.86
Volume: 31,683 Market Cap: 51(M)

Technical analysis

as of: 2023-03-31 4:21:20 PM
Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 3.52     One year: 4.11
Support: Support1: 2.88    Support2: 2.79
Resistance: Resistance1: 3.01    Resistance2: 3.52
Pivot: 2.86
Moving Average: MA(5): 2.85     MA(20): 2.88
MA(100): 2.93     MA(250): 2.63
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 35     %D(3): 25.5
RSI: RSI(14): 51.7
52-week: High: 3.09  Low: 1.85
Average Vol(K): 3-Month: 52 (K)  10-Days: 32 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PMCB ] has closed below upper band by 9.2%. Bollinger Bands are 44.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.94 - 2.96 2.96 - 2.97
Low: 2.83 - 2.84 2.84 - 2.86
Close: 2.89 - 2.91 2.91 - 2.93

Company Description

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Headline News

Wed, 29 Mar 2023
Is Pharmacyte Biotech Inc (PMCB) Stock About to Get Hot Wednesday? - InvestorsObserver

Mon, 27 Mar 2023
Should Biotechnology Stock Pharmacyte Biotech Inc (PMCB) Be in Your Portfolio Monday? - InvestorsObserver

Wed, 15 Mar 2023
Pharmacyte Biotech Inc (PMCB) is down -4.04% in a Week, Should You Hold? - InvestorsObserver

Tue, 14 Feb 2023
Is Pharmacyte Biotech Inc (PMCB) a Smart Choice in Biotechnology Tuesday? - InvestorsObserver

Thu, 02 Feb 2023
PharmaCyte Biotech to Implement Second $10-Million Share ... - Business Wire

Fri, 07 Oct 2022
PharmaCyte Biotech Board of Directors Announces Business ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 19 (M)
Shares Float 13 (M)
% Held by Insiders 10.3 (%)
% Held by Institutions 36 (%)
Shares Short 46 (K)
Shares Short P.Month 80 (K)

Stock Financials

EPS -0.01
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -4.6
Return on Equity (ttm) -6.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -4 (M)
Levered Free Cash Flow -3 (M)

Stock Valuations

PE Ratio -1455
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -12.25

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.